Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform.
This collaboration is an important step forward for cell therapy development and manufacturing with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more patients.
“Cell therapy manufacturing infrastructure and its associated costs have severely limited the accessibility of cell therapies. Multiply Labs’ automation strategy has the potential to modularize and simplify cell therapy production to ensure greater patient impact. We are very excited to contribute to the Multiply Labs team’s vision by integrating our next generation cell engineering approach with their robotics,” said Armon Sharei, Founder and CEO of Portal.
Portal’s mechanoporation technology has demonstrated the capability to deliver many different types of cargo to a broad range of cell types while preserving normal cell function. By enabling robust multiplexed engineering of cells, this approach can enable a broad range of novel cell therapies. This partnership will add automation support for Portal’s platform and overall approach to intracellular delivery, improving efficiency, throughput, and speed, while reducing the risk of human error. The companies aim to develop a Robotic Mechanoporation Cartridge that will contain Portal’s hardware consumable kit, enabling Multiply Labs’ robotic systems to autonomously operate Portal’s mechanoporation technology.
“We are honored to welcome Portal Biotechnologies into our industry-leading partner ecosystem,” said Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs. “It is crucial that we partner with companies like Portal, who are on the cutting edge of drug discovery and cellular therapeutics, to support their scalability through automation. Together, we are primed to address some of the largest barriers that exist in cell therapy today, ensuring future patients can benefit from the life-saving potential of these treatments.”
Multiply Labs’ automation technology for cell therapy manufacturing is a unique approach that is based on being compatible with the leading GMP-grade instruments, consumables, and reagents. In support of this strategy, Multiply Labs recently published pre-print data demonstrating that automated and manual cell expansion processes are statistically equivalent. This implies that manufacturers can automate their current cell expansion protocols with minimal alterations and reduced regulatory risk.
Many stakeholders in the cell therapy space will benefit from this collaboration by integrating Portal’s cutting-edge solutions while enjoying the advantages of automation, such as cost reduction and increased throughput.
About Multiply Labs:
Multiply Labs is a robotics company that provides autonomous manufacturing technology to the pharmaceutical industry. The company develops advanced, cloud-controlled robotic systems that enable the production of individualized drugs at scale. Its customers include some of the largest global organizations in the advanced pharmaceutical manufacturing space. Multiply Labs’ expertise is at the intersection of robotics and biopharma – its team includes mechanical engineers, electrical engineers, computer scientists, software engineers and pharmaceutical scientists. The founding team got in touch because of their shared love of robots at MIT. The company is based in San Francisco, California.
For more information, please visit www.multiplylabs.com.
